Metropolitan Life Insurance CO Arvinas, Inc. Transaction History

Metropolitan Life Insurance CO

  • $252 Million
  • Q4 2024

Shares

34 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024
SELL
$36.38 - $52.31 $6,039 - $8,683
-166 Reduced 5.92%
2,636 $108,000
Q4 2023

Feb 14, 2024
SELL
$14.19 - $42.33 $3,590 - $10,709
-253 Reduced 8.28%
2,802 $115,000
Q3 2023

Nov 14, 2023
BUY
$19.64 - $28.21 $5,715 - $8,209
291 Added 10.53%
3,055 $60,000
Q1 2023

May 15, 2023
SELL
$26.15 - $37.26 $5,439 - $7,750
-208 Reduced 7.0%
2,764 $75,000
Q4 2022

Jun 14, 2023
BUY
$32.47 - $57.24 $6,753 - $11,905
208 Added 7.53%
2,972 $102 Million
Q3 2022

Jun 14, 2023
BUY
$41.87 - $57.99 $8,708 - $12,061
208 Added 7.53%
2,972 $132 Million
Q2 2022

Jun 20, 2023
BUY
$36.01 - $74.24 $7,490 - $15,441
208 Added 7.53%
2,972 $125,000
Q1 2022

Jun 20, 2023
BUY
$60.27 - $81.57 $12,536 - $16,966
208 Added 7.53%
2,972 $200,000
Q1 2022

Mar 30, 2023
SELL
$60.27 - $81.57 $549,119 - $743,184
-9,111 Reduced 75.4%
2,972 $200,000
Q1 2022

May 12, 2022
SELL
$60.27 - $81.57 $549,119 - $743,184
-9,111 Reduced 75.4%
2,972 $200,000
Q4 2021

Jun 21, 2023
BUY
$65.85 - $96.21 $613,656 - $896,580
9,319 Added 337.16%
12,083 $992,000
Q4 2021

Mar 30, 2023
BUY
$65.85 - $96.21 $39,970 - $58,399
607 Added 5.29%
12,083 $992,000
Q4 2021

Feb 15, 2022
BUY
$65.85 - $96.21 $39,970 - $58,399
607 Added 5.29%
12,083 $992,000
Q3 2021

Jun 21, 2023
BUY
$73.2 - $107.87 $637,718 - $939,763
8,712 Added 315.2%
11,476 $943,000
Q3 2021

Mar 30, 2023
SELL
$73.2 - $107.87 $38,796 - $57,171
-530 Reduced 4.41%
11,476 $943,000
Q3 2021

Nov 15, 2021
SELL
$73.2 - $107.87 $38,796 - $57,171
-530 Reduced 4.41%
11,476 $943,000
Q2 2021

Jun 21, 2023
BUY
$60.45 - $84.26 $558,678 - $778,730
9,242 Added 334.37%
12,006 $924,000
Q2 2021

Mar 30, 2023
BUY
$60.45 - $84.26 $140,727 - $196,157
2,328 Added 24.05%
12,006 $924,000
Q2 2021

Aug 16, 2021
BUY
$60.45 - $84.26 $725,158 - $1.01 Million
11,996 Added 119960.0%
12,006 $924,000
Q1 2021

Jun 26, 2023
BUY
$58.19 - $91.37 $402,325 - $631,732
6,914 Added 250.14%
9,678 $640 Million
Q1 2021

May 14, 2021
SELL
$58.19 - $91.37 $562,580 - $883,365
-9,668 Reduced 99.9%
10 $640,000
Q4 2020

Jun 22, 2023
BUY
$20.19 - $84.93 $139,593 - $587,206
6,914 Added 250.14%
9,678 $821,000
Q4 2020

Mar 30, 2023
BUY
$20.19 - $84.93 $10,175 - $42,804
504 Added 5.49%
9,678 $821,000
Q4 2020

Feb 16, 2021
BUY
$20.19 - $84.93 $10,175 - $42,804
504 Added 5.49%
9,678 $822,000
Q3 2020

Jun 26, 2023
BUY
$22.99 - $36.34 $147,365 - $232,939
6,410 Added 231.91%
9,174 $216,000
Q2 2020

Jun 26, 2023
BUY
$29.88 - $56.74 $191,530 - $363,703
6,410 Added 231.91%
9,174 $307,000
Q2 2020

Mar 30, 2023
BUY
$29.88 - $56.74 $84,201 - $159,893
2,818 Added 44.34%
9,174 $307,000
Q2 2020

Aug 14, 2020
BUY
$29.88 - $56.74 $84,201 - $159,893
2,818 Added 44.34%
9,174 $308,000
Q1 2020

Jul 12, 2023
BUY
$33.0 - $54.5 $118,536 - $195,764
3,592 Added 129.96%
6,356 $256,000
Q4 2019

Jul 12, 2023
BUY
$15.39 - $44.38 $55,280 - $159,412
3,592 Added 129.96%
6,356 $261,000
Q3 2019

Jul 12, 2023
BUY
$21.55 - $27.61 $77,407 - $99,175
3,592 Added 129.96%
6,356 $136,000
Q3 2019

Mar 30, 2023
BUY
$21.55 - $27.61 $72,925 - $93,432
3,384 Added 113.86%
6,356 $136,000
Q3 2019

Nov 14, 2019
BUY
$21.55 - $27.61 $136,971 - $175,489
6,356 New
6,356 $137,000
Q2 2019

Jul 12, 2023
SELL
$15.96 - $23.8 $21,992 - $32,796
-1,378 Reduced 49.86%
1,386 $30.5 Million

Others Institutions Holding ARVN

# of Institutions
224
Shares Held
70.9M
Call Options Held
1.52M
Put Options Held
346K
View Full List

About ARVINAS, INC.

ARVN Quotes by TradingView
  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $986M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email